Azo-inserted responsive hybrid liposomes for hypoxia-specific drug delivery. (1st October 2020)

• Record Type: Journal Article
• Authors: Long, Mengmeng; Lu, Ailing; Lu, Min; Weng, Lingyan; Chen, Qiuping; Zhu, Li; Chen, Zhongping
• Is Part Of: Acta biomaterialia. Volume 115(2020)
• Page Start: 343
• Page End: 357
• Publication Date: 2020-10-01
• Subjects: Azo -- Hybrid liposomes -- Hypoxia -- HIF-1α -- Targeted drug delivery; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2020.07.061
• Languages: English
• ISSNs: 1742-7061

Abstract

Abstract: Stimuli-responsive drug delivery systems using endogenous stimuli from tumor microenvironments such as acidic pH, over-expressed enzyme, and high redox potential as triggers have shown tremendous promise in cancer therapy. However, their clinical application is severely limited because of tumor heterogeneity. Hypoxia, a physiological feature observed in almost all solid tumors and even in nodules with very small size, has currently emerged as a more general but efficient stimulus to trigger release. Herein, we developed hypoxia-responsive hybrid liposomes (HR-HLPs), composed of azo-inserted organokoxysilane-based lipid analogue as a responsive component and commercial phospholipid for reducing the rigidity of liposomal membrane caused by azo, for drug delivery targeting tumor hypoxia. HR-HLPs had the advantages of high structural stability to avoid premature drug leakage when circulating in the blood and high sensitivity in responding to hypoxia once reaching tumor sites. HR-HLPs exhibit deep tumor penetration capability, enabling effective delivery to hypoxic regions distant from tumor vessels. Moreover, HR-HLPs could selectively release their payload, co-localizing with over-expressed hypoxia inducible factor 1α (HIF-1α) in vitro and in vivo . As a result, HR-HLPs showed improved therapeutic outcome accompanied by reduced adverse effects. The results highlighted the potential application of azo-inserted responsive hybrid liposomes for hypoxia-targeted drug delivery. Statement of Significance: 1. A hypoxia-responsive hybrid liposomal drug delivery system is developed for specific drug delivery targeting tumor hypoxia. 2. The hybrid liposomes have high structural stability to avoid premature drug leakage under normal physiological condition and high sensitivity in responding to hypoxia once reaching tumor sites. 3. The hybrid liposomes exhibit deep tumor penetration capability, enabling effective delivery to hypoxic regions distant from tumor vessels and co-localization with over-expressed HIF-1α in vitro and in vivo . Graphical abstract: Image, graphical abstract